Dr. Clint E. Behrend, M.D.
Gastroenterology (Gastroenterology Physician)
2770 Cortez Ave
Idaho Falls, ID 83404
Who else practices at this address →
Bonneville County includes primary care (1% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (1992)
- Years since graduation
- 34
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 470
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1992Medical school: University of Maryland School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
ID license M7328
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mountain View Hospital Idaho Falls, ID
- Eastern Idaho Regional Medical Center Idaho Falls, ID
- Idaho Falls Community Hospital, LLC Idaho Falls, ID
- Madison Memorial Hospital Rexburg, ID
- Teton Valley Hospital Driggs, ID
Medical groups
- Mountain View Hospital LLC (276 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 470
- Services billed
- 916
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 130 | 129 |
| Established patient office or other outpatient visit, 30-39 minutes | 121 | 107 |
| Biopsy of large bowel using a flexible endoscope | 105 | 104 |
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 95 | 91 |
| New patient office or other outpatient visit, 45-59 minutes | 85 | 85 |
| Insertion of guide wire with dilation of esophagus using a flexible endoscope | 65 | 64 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 31 | 31 |
| Established patient office or other outpatient visit, 20-29 minutes | 30 | 30 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 26 | 26 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 26 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Famotidine Other prescribers in Idaho Falls, ID | 576 |
| Omeprazole Other prescribers in Idaho Falls, ID | 533 |
| Sod Sulf-Potass Sulf-Mag Sulf (sodium, potassium,mag sulfates) Other prescribers in Idaho Falls, ID | 237 |
| Metoclopramide Hcl Other prescribers in Idaho Falls, ID | 184 |
| Sucralfate Other prescribers in Idaho Falls, ID | 179 |
| Colestipol Hcl Other prescribers in Idaho Falls, ID | 119 |
| Pantoprazole Sodium Other prescribers in Idaho Falls, ID | 45 |
| Esomeprazole Magnesium Other prescribers in Idaho Falls, ID | 44 |
| Budesonide Dr (budesonide) Other prescribers in Idaho Falls, ID | 40 |
| Azathioprine Other prescribers in Idaho Falls, ID | 38 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 38 payments worth $631 in total to this clinician.
| AbbVie Inc. | $193 |
|---|---|
| Janssen Biotech, Inc. | $69.00 |
| Madrigal Pharmaceuticals | $60.52 |
| Phathom Pharmaceuticals, Inc. | $56.13 |
| Takeda Pharmaceuticals U.S.A., Inc. | $38.44 |
| Aimmune Therapeutics, Inc. | $35.25 |
| Genzyme Corporation | $32.39 |
| Celltrion USA Inc. | $25.94 |
| Food and Beverage | $631 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $125,244 in research payments for these studies, mostly to the institutions running them.
- UC P3: Double-Blind Treat Straight Through
Genentech, Inc. - A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
Genentech, Inc. - UC P3: Double-Blind Treat Straight Through
F. Hoffmann-la Roche AG - A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
F. Hoffmann-la Roche AG - A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD)
AbbVie Inc. - A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
Ferring Pharmaceuticals As - A Long-Term Registry of Humira (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. - A Long-Term Registry of Humira® (Adalimumab) in Patients With Moderately to Severely Active Ulcerative Colitis (UC)
AbbVie Inc. · Completed · NCT01848561
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.